文献速递药物相互作用

利特昔替尼作为CYP450底物及抑制剂的药物相互作用特征

Drug-drug interaction profile of ritlecitinib as perpetrator and victim through cytochrome P450.
PubMed 文献 · Br J Clin Pharmacol · 2025-05-07

该研究分析7项临床试验,评估强CYP3A抑制剂/诱导剂对利特昔替尼药代动力学的影响,以及利特昔替尼对多种CYP底物(咪达唑仑、依非韦伦、甲苯磺丁脲、咖啡因、口服避孕药)的影响。结果显示利特昔替尼是CYP3A和CYP1A2的中度抑制剂,强CYP诱导剂可降低利特昔替尼暴露但未至临床相关水平。

要点

  • 利特昔替尼是CYP3A和CYP1A2的中度抑制剂。
  • 强CYP诱导剂可降低利特昔替尼暴露,但未至临床相关水平。
  • 利特昔替尼对依非韦伦、甲苯磺丁脲、左炔诺孕酮药代动力学无影响。

核心结论

  • 利特昔替尼是CYP3A和CYP1A2的中度抑制剂。
  • 强CYP诱导剂可降低利特昔替尼浓度,但未至导致缺乏获益的临床相关水平。

研究设计与样本

  • 分析7项健康成人临床药物相互作用研究,以血浆药代动力学参数评估利特昔替尼作为肇事药或受害药的相互作用潜力。

主要发现

  • 合用利特昔替尼时,咪达唑仑AUCinf增加约169%,Cmax增加约80.1%。
  • 合用利特昔替尼时,咖啡因AUCinf增加约165%,Cmax增加约10%。
  • 依非韦伦AUC0-72和Cmax在合用与不合用利特昔替尼时相似;甲苯磺丁脲AUCinf和Cmax不受多剂量利特昔替尼影响。
  • 多剂量利特昔替尼200 mg每日一次合用时,炔雌醇AUCinf降低约18%,Cmax降低约12%;多剂量50 mg每日一次合用时未见相关变化;左炔诺孕酮药代动力学不受利特昔替尼剂量影响。
  • 多剂量伊曲康唑合用时利特昔替尼AUCinf增加约15%;多剂量利福平合用时利特昔替尼AUCinf降低约45%。

关键数值与推荐

  • 利特昔替尼是CYP3A和CYP1A2的中度抑制剂。
  • 强CYP诱导剂可降低利特昔替尼浓度,但未至导致缺乏获益的临床相关水平。

临床怎么用

  • 临床合用时需关注利特昔替尼对CYP3A和CYP1A2底物(如咪达唑仑、咖啡因)暴露的增加。
  • 与强CYP诱导剂合用时,利特昔替尼暴露降低但未至临床相关水平,可能无需调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To assess the effect of a potent cytochrome P450 (CYP) 3A inhibitor and CYP inducer on the pharmacokinetics of ritlecitinib, a JAK3/TEC family kinase inhibitor, and assess the effect of ritlecitinib on the pharmacokinetics of CYP substrates (midazolam, efavirenz, tolbutamide, caffeine and oral contraceptives [ethinyl oestradiol and levonorgestrel]) in healthy adults. METHODS: Seven clinical drug-drug interaction studies were analysed. Pharmacokinetic parameters for drugs as measured in blood plasma were used to estimate the drug interaction potential with ritlecitinib as a perpetrator or victim. RESULTS: Midazolam exposure (area under plasma concentration-time curve from time 0 to infinity [AUCinf]) and peak exposure (maximum concentration [Cmax]) were increased by ≈169% and ≈80.1%, respectively, in the presence of ritlecitinib. Efavirenz exposure (AUC0-72) and peak exposure (Cmax) were similar in the presence and absence of ritlecitinib coadministration. Tolbutamide pharmacokinetic parameters (AUCinf and Cmax) were not affected by multiple ritlecitinib doses. In the presence of ritlecitinib, AUCinf and Cmax of caffeine increased by ≈165% and ≈10%, respectively. AUCinf and Cmax of ethinyl oestradiol decreased by ≈18% and ≈12%, respectively, following coadministration of multiple ritlecitinib 200 mg once-daily doses, but no relevant change was observed following multiple 50 mg once-daily doses. Ritlecitinib doses did not affect the pharmacokinetics of levonorgestrel. Coadministration following multiple itraconazole doses increased ritlecitinib AUCinf by ≈15%. Coadministration following multiple rifampicin doses decreased AUCinf of ritlecitinib by ≈45%. CONCLUSIONS: Ritlecitinib is a moderate inhibitor of CYP3A and CYP1A2. Strong CYP inducers can reduce ritlecitinib concentrations, but not to clinically relevant levels leading to lack of benefit.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Purohit VS, Huh Y, Dowty ME, et al. Drug-drug interaction profile of ritlecitinib as perpetrator and victim through cytochrome P450. Br J Clin Pharmacol. 2025. PMID: 40331456. doi:10.1002/bcp.70069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。